🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰 Latest breakthroughs
🗺️ Disease Atlas · Hematologic disorder

B-cell chronic lymphocytic leukemia

B-cell chronic lymphocytic leukemia (B-CLL) is a type of B-cell non-Hodgkin lymphoma, and the most common form of leukemia in Western countries, affecting elderly adults (mean age of 67 and 72 years) with a slight male predominance (1.7:1), and characterized by a highly variable clinical presentation that can include asymptomatic disease or non-specific B-symptoms such as unintentional weight loss, severe fatigue, f…

🔔 Follow weekly
🧬5326genes / proteins with evidence
💊345drugs and clinical candidates
🧪12+recruiting trials worldwide
✅14approved
📈35phase 3
🧬

Understand B-cell chronic lymphocytic leukemia

Cancer · Cells that grow out of control
🎓 Learn more

What it is

Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job:

White blood cells help your body fight infection

Red blood cells deliver oxygen from your lungs to your tissues and organs

From MedlinePlus: Chronic Lymphocytic Leukemia (US National Library of Medicine) ↗

🧬 Cancer: Cancer is a group of diseases in which some of the body's cells grow and divide without control, and can spread to other parts of the body.

❓ Why it happens

  • Changes (mutations) build up in the genes that tell a cell when to grow, divide and die.
  • Most of these changes happen during life: tobacco, too much sun, alcohol, some infections (such as HPV and hepatitis B and C), radiation, obesity and ageing all raise the risk.
  • Some people inherit a faulty gene that raises their risk, such as BRCA1 or BRCA2.

🫀 What it does to the body

  • Cancer cells form a lump (tumour) that can press on or invade nearby organs.
  • They can travel through the blood or lymph to start new tumours elsewhere (metastasis).
  • Blood cancers crowd out healthy blood cells in the bone marrow.

🧱 Why it is hard to cure

  • Every cancer is different, even between two people with the same type - and inside one tumour.
  • Cancer cells keep changing, so they can learn to resist a medicine that worked at first.
  • Cancer cells are the body's own cells, so killing them without harming healthy cells is hard.
  • Many cancers cause no symptoms until they have spread, and a new medicine often takes more than ten years to go from the lab to patients.

🚀 What research is trying now

  • Targeted medicines against the exact gene change in a tumour (for example EGFR, ALK or KRAS).
  • Immunotherapy that helps the immune system recognise cancer, including CAR-T cell therapy.
  • Personalised cancer vaccines built from each tumour's mutations, now in late trials.
  • Blood tests that look for tumour DNA to find cancer earlier, and AI to read scans and slides.

General information about cancer, reviewed by people; it does not describe any one person. Below: the evidence for B-cell chronic lymphocytic leukemia itself.

🤖

AI briefing

Where the science on B-cell chronic lymphocytic leukemia stands, from the evidence on this page

AI reads the targets, drugs, trials and papers below and writes where the science stands — every claim cited. It is shared with everyone who opens B-cell chronic lymphocytic leukemia.

Sign in to ask AI
🎯

Top targets

Genes and proteins ranked by Open Targets evidence (0-1)
NOTCH1 notch receptor 1PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.75
BCL2 BCL2 apoptosis regulatorPROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.74
SF3B1 splicing factor 3b subunit 1PROTACsmall molecule🧊 AlphaFold structure ↗ 0.74
BTK Bruton tyrosine kinasePROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.72
CHD2 chromodomain helicase DNA binding protein 2PROTAC🧊 AlphaFold structure ↗ 0.71
MYD88 MYD88 innate immune signal transduction adaptorPROTACantibody🧊 AlphaFold structure ↗ 0.70
TP53 tumor protein p53PROTACothersmall molecule🧊 AlphaFold structure ↗ 0.69
POLE DNA polymerase epsilon, catalytic subunitPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.66
POLD1 DNA polymerase delta 1, catalytic subunitPROTACsmall molecule🧊 AlphaFold structure ↗ 0.66
XPO1 exportin 1PROTACsmall molecule🧊 AlphaFold structure ↗ 0.64
IRF4 interferon regulatory factor 4PROTAC🧊 AlphaFold structure ↗ 0.64
ATM ATM serine/threonine kinasePROTACsmall molecule🧊 AlphaFold structure ↗ 0.64
MS4A1 membrane spanning 4-domains A1PROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.63
POT1 protection of telomeres 1PROTAC🧊 AlphaFold structure ↗ 0.62
PIK3CD phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit deltaPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.61

Green labels: what the target is known to be druggable by. The score combines genetics, somatic mutations, drugs, expression and literature.

💊

Drugs and candidates

Every medicine linked to B-cell chronic lymphocytic leukemia, by how far it has got
Approved · 14
AcalabrutinibTyrosine-protein kinase BTK inhibitorApproved
Acalabrutinib MaleateTyrosine-protein kinase BTK inhibitorApproved
AlemtuzumabCAMPATH-1 antigen inhibitorApproved
Bendamustine HydrochlorideApproved
DuvelisibPI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitorApproved
Duvelisib MonohydratePI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitorApproved
Show all 14
Fludarabine PhosphateRibonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) …Approved
IbrutinibTyrosine-protein kinase BTK inhibitorApproved
IdelalisibPI3-kinase p110-delta subunit inhibitorApproved
ObinutuzumabB-lymphocyte antigen CD20 binding agentApproved
OfatumumabB-lymphocyte antigen CD20 binding agentApproved
RituximabB-lymphocyte antigen CD20 binding agentApproved
VenetoclaxApoptosis regulator Bcl-2 inhibitorApproved
ZanubrutinibTyrosine-protein kinase BTK inhibitorApproved
In phase 2 / 3 · 20
Apg-2575Apoptosis regulator Bcl-2 inhibitorPhase 3
Arsenic TrioxideThioredoxin reductase 1 inhibitorPhase 3
BendamustinePhase 3
ChlorambucilPhase 3
CladribinePhase 3
CyclophosphamidePhase 3
Show all 20
Darbepoetin AlfaErythropoietin receptor agonistPhase 3
DinaciclibCyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitorPhase 3
Doxorubicin HydrochlorideDNA topoisomerase II alpha inhibitorPhase 3
Epoetin AlfaErythropoietin receptor agonistPhase 3
Epoetin BetaErythropoietin receptor agonistPhase 3
ErgocalciferolVitamin D receptor agonistPhase 3
FilgrastimGranulocyte colony stimulating factor receptor agonistPhase 3
FludarabinePhase 3
Iron SucrosePhase 3
LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulatorPhase 3
Lisocabtagene MaraleucelB-lymphocyte antigen CD19 binding agentPhase 3
MethylprednisoloneGlucocorticoid receptor agonistPhase 3
Mitoxantrone HydrochlorideDNA topoisomerase II alpha inhibitorPhase 3
NemtabrutinibPhase 3
Early trials · 20
AcadesineAMP-activated protein kinase, AMPK activatorPhase 1/2
Aeg-35156Phase 1/2
AvadomidePhase 1/2
BeclanorsenPhase 1/2
BlinatumomabT cell surface glycoprotein CD3 cross-linking agent; B-lymphocyte antigen CD19 cross-link…Phase 1/2
CamonsertibPhase 1/2
Show all 20
Carfilzomib26S proteasome inhibitorPhase 1/2
Cdc-801Phase 1/2
Cemacabtagene AnsegedleucelPhase 1/2
CerdulatinibTyrosine-protein kinase SYK inhibitor; Tyrosine-protein kinase JAK1 inhibitorPhase 1/2
Cho-H01Phase 1/2
ClofarabineRibonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) …Phase 1/2
Cyc-065Phase 1/2
DacetuzumabTumor necrosis factor receptor superfamily member 5 inhibitorPhase 1/2
DaporinadNicotinamide phosphoribosyltransferase inhibitorPhase 1/2
Dexamethasone Phosphoric AcidGlucocorticoid receptor agonistPhase 1/2
Dexamethasone Sodium PhosphateGlucocorticoid receptor agonistPhase 1/2
DoxycyclineMatrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitorPhase 1/2
DubermatinibPhase 1/2
Epigalocatechin GallatePhase 1/2
🧪

Recruiting trials

Worldwide, open to new patients now
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leuke…NCT05281809 · Phase 2 · 📍 PittsburghA Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic MalignanciesNCT05908409 · Phase 1, Phase 2 · 📍 SantanderLong-Term Follow-up of Patients Treated With Miltenyi Cell and Gene TherapiesNCT06508775 · NA · 📍 BerlinNemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphoc…NCT07557056 · Phase 2 · 📍 ColumbusQ702 for the Treatment of Patients With Hematologic MalignanciesNCT06712810 · Phase 1 · 📍 ScottsdaleThe Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia…NCT05876923 · NA · 📍 ScottsdaleWisconsin Ginseng for Decreasing Cancer Related FatigueNCT06395441 · Phase 3 · 📍 Albert LeaA Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Pa…NCT07422337 · n/a · 📍 Little RockAllo HSCT Using RIC and PTCy for Hematological DiseasesNCT05805605 · Phase 2 · 📍 MinneapolisThe Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Tran…NCT01890486 · n/a · 📍 Winston-SalemSafety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic MalignanciesNCT06037018 · Phase 1 · 📍 TianjinSingle-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Trea…NCT07648264 · Phase 3 · 📍 Orange Search more trials →
📚

Newest research

Latest papers on PubMed
Expression of TCTP/HRF and MCL-1 in chronic lymphocytic leukemia: implications for disease pathogenesis.Mol Biol Rep 2026 · PMID 42927534PTPN2/PTPN1 inhibition enhances ex vivo T- cell responses and potentiates mosunetuzumab activity in chronic lymphocytic leukemia.Front Immunol 2026 · PMID 42922970The genomic and transcriptomic landscape of chronic lymphocytic leukaemia: Insights from an integrated analysis of 275 patients.Br J Haematol 2026 · PMID 42922293Pulmonary Involvement in Chronic Lymphocytic Leukemia: A Structured Diagnostic Approach to Diffuse Infiltrates-A Case Report.EJHaem 2026 · PMID 42910155Case Report: Durable, well-tolerated complete response to epcoritamab plus pirtobrutinib in Richter transformation relapsing afte…Front Med (Lausanne) 2026 · PMID 42908725Acute and long-term outcomes of CD20-targeting CAR T-cell therapy in relapsed or refractory B-NHL: MB-CART20.1 Lymphoma phase I t…Eur J Cancer 2026 · PMID 42906410IκBζ target genes in chronic lymphocytic leukemia.iScience 2026 · PMID 42903746Survival Outcomes in Chronic Lymphocytic Leukemia During the Novel Agent Era: A Population-Based Analysis.Cancer Med 2026 · PMID 42897340 Ask a research question in the Hypothesis Lab →
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy